Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Analyst Ratings Changes

RCKT has been the topic of several research reports. William Blair reaffirmed an "outperform" rating on shares of Rocket Pharmaceuticals in a research report on Thursday, May 5th. Raymond James upped their target price on Rocket Pharmaceuticals from $22.00 to $24.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th. Needham & Company LLC decreased their target price on Rocket Pharmaceuticals from $75.00 to $62.00 and set a "buy" rating on the stock in a research report on Tuesday, May 17th. Stifel Nicolaus upped their target price on Rocket Pharmaceuticals from $63.00 to $67.00 in a research report on Thursday, May 19th. Finally, Chardan Capital upped their target price on Rocket Pharmaceuticals from $60.00 to $62.00 and gave the company a "buy" rating in a research report on Thursday, May 19th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $55.80.

Rocket Pharmaceuticals Trading Down 1.6 %

Shares of RCKT Stock opened at $17.64 on Thursday. The stock has a 50 day simple moving average of $14.74 and a 200 day simple moving average of $14.38. The company has a current ratio of 13.41, a quick ratio of 13.41 and a debt-to-equity ratio of 0.05. Rocket Pharmaceuticals has a 1 year low of $7.57 and a 1 year high of $37.44. The stock has a market cap of $1.16 billion, a P/E ratio of -5.92 and a beta of 1.68.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Rating) last released its earnings results on Monday, August 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.16). During the same period in the previous year, the company posted ($0.55) earnings per share. On average, research analysts predict that Rocket Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.